1.	BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 11-080, NCT01453595
2.	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235A2101, 2006-004353-23, NCT00620594
3.	PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: VICC BRE 1055, NCT01248494
4.	A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235A2118, 2010-022331-11, NCT01285466
5.	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CMEK162X2103, 2011-000421-74, NCT01337765
6.	A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235B2203, NCT01471847